CL2007001700A1 - Formas cristalinas 2 y 3 del acido (trans-4-{4-((5-(3,4-difluorofenil)amino}-1,3,4-oxadiazol-2-il)carbonil)amino}fenil)ciclohexil)acetico;composicion farmaceutica que comprende a dicho compuesto;y su uso para inhibir la actividad de diacilglicerol aciltransferasa (dgat1) - Google Patents
Formas cristalinas 2 y 3 del acido (trans-4-{4-((5-(3,4-difluorofenil)amino}-1,3,4-oxadiazol-2-il)carbonil)amino}fenil)ciclohexil)acetico;composicion farmaceutica que comprende a dicho compuesto;y su uso para inhibir la actividad de diacilglicerol aciltransferasa (dgat1)Info
- Publication number
- CL2007001700A1 CL2007001700A1 CL2007001700A CL2007001700A CL2007001700A1 CL 2007001700 A1 CL2007001700 A1 CL 2007001700A1 CL 2007001700 A CL2007001700 A CL 2007001700A CL 2007001700 A CL2007001700 A CL 2007001700A CL 2007001700 A1 CL2007001700 A1 CL 2007001700A1
- Authority
- CL
- Chile
- Prior art keywords
- amino
- oxadiazol
- difluorophenyl
- cyclohexyl
- trans
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Molecular Biology (AREA)
Abstract
Forma cristalina del ácido (trans-4-(4-[((5-[(3,4-difluorofenil)amino]-1,3,4-oxadiazol-2-il)carbonil)amino]fenil)ciclohexil)acético; composición farmacéutica que comprende a dicho compuesto; y su uso para inhibir la actividad de la coenzima A.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0611552.1A GB0611552D0 (en) | 2006-06-12 | 2006-06-12 | Chemical compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2007001700A1 true CL2007001700A1 (es) | 2008-01-18 |
Family
ID=36745696
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2007001700A CL2007001700A1 (es) | 2006-06-12 | 2007-06-11 | Formas cristalinas 2 y 3 del acido (trans-4-{4-((5-(3,4-difluorofenil)amino}-1,3,4-oxadiazol-2-il)carbonil)amino}fenil)ciclohexil)acetico;composicion farmaceutica que comprende a dicho compuesto;y su uso para inhibir la actividad de diacilglicerol aciltransferasa (dgat1) |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP2041101A1 (es) |
JP (1) | JP2009539954A (es) |
KR (1) | KR20090015980A (es) |
CN (1) | CN101466690A (es) |
AR (1) | AR061332A1 (es) |
AU (1) | AU2007259031A1 (es) |
BR (1) | BRPI0712354A2 (es) |
CA (1) | CA2653550A1 (es) |
CL (1) | CL2007001700A1 (es) |
GB (1) | GB0611552D0 (es) |
IL (1) | IL195348A0 (es) |
MX (1) | MX2008015762A (es) |
NO (1) | NO20084963L (es) |
TW (1) | TW200815378A (es) |
UY (1) | UY30404A1 (es) |
WO (1) | WO2007144571A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7795283B2 (en) | 2004-12-14 | 2010-09-14 | Astrazeneca Ab | Oxadiazole derivative as DGAT inhibitors |
JP2009520786A (ja) | 2005-12-22 | 2009-05-28 | アストラゼネカ アクチボラグ | Dgat阻害剤として使用するためのピリミド−[4,5−b]−オキサジン |
PT2402319T (pt) | 2006-03-31 | 2017-12-11 | Novartis Ag | Inibidores de dgat |
AU2007266890B2 (en) | 2006-05-30 | 2011-02-17 | Astrazeneca Ab | 1, 3, 4 -oxadiazole derivatives as DGAT1 inhibitors |
US8084478B2 (en) | 2006-05-30 | 2011-12-27 | Asstrazeneca Ab | Substituted 5- phenylamino- 1, 3, 4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme A diacylglycerol acyltransferase |
WO2008099221A1 (en) * | 2007-02-15 | 2008-08-21 | Prosidion Limited | Amide and urea derivatives for the treatment of metabolic diseases |
AR066169A1 (es) | 2007-09-28 | 2009-07-29 | Novartis Ag | Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat |
ES2535083T3 (es) | 2007-12-20 | 2015-05-05 | Astrazeneca Ab | Compuestos de carbamoilo como inhibidores 190 de DGAT1 |
EP3366686B9 (en) | 2009-03-20 | 2021-08-04 | Metabasis Therapeutics, Inc. | Inhibitors of diacylglycerol o-acyltransferase 1 (dgat-1) and uses thereof |
WO2010146395A1 (en) | 2009-06-19 | 2010-12-23 | Astrazeneca Ab | Pyrazine carboxamides as inhibitors of dgat1 |
FR2963005B1 (fr) * | 2010-07-23 | 2012-08-17 | Sanofi Aventis | Derives d'oxadiazoles et de pyridazines, leur preparation et leur application en therapeutique |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR044152A1 (es) * | 2003-05-09 | 2005-08-24 | Bayer Corp | Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad |
US7795283B2 (en) * | 2004-12-14 | 2010-09-14 | Astrazeneca Ab | Oxadiazole derivative as DGAT inhibitors |
-
2006
- 2006-06-12 GB GBGB0611552.1A patent/GB0611552D0/en not_active Ceased
-
2007
- 2007-06-04 TW TW096120008A patent/TW200815378A/zh unknown
- 2007-06-08 BR BRPI0712354-0A patent/BRPI0712354A2/pt not_active Application Discontinuation
- 2007-06-08 KR KR1020087030959A patent/KR20090015980A/ko not_active Application Discontinuation
- 2007-06-08 WO PCT/GB2007/002097 patent/WO2007144571A1/en active Application Filing
- 2007-06-08 JP JP2009514875A patent/JP2009539954A/ja active Pending
- 2007-06-08 CN CNA2007800217295A patent/CN101466690A/zh active Pending
- 2007-06-08 AU AU2007259031A patent/AU2007259031A1/en not_active Abandoned
- 2007-06-08 MX MX2008015762A patent/MX2008015762A/es not_active Application Discontinuation
- 2007-06-08 CA CA002653550A patent/CA2653550A1/en not_active Abandoned
- 2007-06-08 EP EP07733109A patent/EP2041101A1/en not_active Withdrawn
- 2007-06-11 UY UY30404A patent/UY30404A1/es not_active Application Discontinuation
- 2007-06-11 AR ARP070102537A patent/AR061332A1/es not_active Application Discontinuation
- 2007-06-11 CL CL2007001700A patent/CL2007001700A1/es unknown
-
2008
- 2008-11-17 IL IL195348A patent/IL195348A0/en unknown
- 2008-11-26 NO NO20084963A patent/NO20084963L/no unknown
Also Published As
Publication number | Publication date |
---|---|
CN101466690A (zh) | 2009-06-24 |
MX2008015762A (es) | 2009-03-16 |
GB0611552D0 (en) | 2006-07-19 |
UY30404A1 (es) | 2008-01-31 |
CA2653550A1 (en) | 2007-12-21 |
TW200815378A (en) | 2008-04-01 |
NO20084963L (no) | 2009-01-07 |
BRPI0712354A2 (pt) | 2012-06-05 |
JP2009539954A (ja) | 2009-11-19 |
AR061332A1 (es) | 2008-08-20 |
WO2007144571A1 (en) | 2007-12-21 |
AU2007259031A1 (en) | 2007-12-21 |
KR20090015980A (ko) | 2009-02-12 |
IL195348A0 (en) | 2009-08-03 |
EP2041101A1 (en) | 2009-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2007001700A1 (es) | Formas cristalinas 2 y 3 del acido (trans-4-{4-((5-(3,4-difluorofenil)amino}-1,3,4-oxadiazol-2-il)carbonil)amino}fenil)ciclohexil)acetico;composicion farmaceutica que comprende a dicho compuesto;y su uso para inhibir la actividad de diacilglicerol aciltransferasa (dgat1) | |
AR118922A2 (es) | Procesos para la preparación de ácidos de 1,2,4-oxadiazol benzoico | |
TN2012000557A1 (en) | Crystalline form of 4- [5 - [3 -chloro-5 - (trifluoromethyl) phenyl] -4, 5 - dihydro - 5 - (trifluoromethyl) -3 - isoxazolyl] -n- [2-0x0-2- [ ( 2, 2, 2 - trifluoroethyl) amino] ethyl] -1- naphthalenecarboxamide | |
PE20090815A1 (es) | Compuesto de amida | |
AR116394A2 (es) | Mesilato de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato | |
NZ594537A (en) | Compounds, compositions, and methods for preventing metastasis of cancer cells | |
CL2012001171A1 (es) | Procedimiento para la preparacion del ester n-[[2-[[[4-[[[(hexiloxicarbonil)]4-amino]iminometil]fenil]amino]metil]1-alquil-1h-benzimidazol-5-il]carbonil]n-2-piridinil-etilico de beta-alanina; y uno de los compuestos intermediarios considerados. | |
UY31385A1 (es) | Composicion farmacéutica de n-(3-metoxi-5-metilpirazin-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil)piridin-3-sulfonamida | |
CL2011001389A1 (es) | Compuestos derivados de isoxazolina; composicion que comprende a uno de los compuestos; y uso de los compuestos en el control de parasitos. | |
AR094588A2 (es) | Proceso de obtención de un compuesto derivado de benzimidazol y composición farmacéutica | |
PE20121045A1 (es) | Agonista de gpr119 | |
MX338024B (es) | Derivado de dibencilamina opticamente activa y metodo para prepararla. | |
PE20120430A1 (es) | Dicianopiridinas alquilamino-sustituidas | |
PE20100083A1 (es) | Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar | |
RS54725B1 (sr) | Benzen sulfonamid tiazol i jedinjenja oksazola | |
SV2009002865A (es) | Uso de oxazolidinonas para el tratamiento y profilaxis de microangiopatias | |
CL2007002422A1 (es) | Tartrato de 1-[2-fluoro-4-(trifluorometil)fenil]3-(3-{[4-metil-5-(4-metil-1,3-oxazol-5-il)-4h-1,2,4-triazol-3-il]tio}propil)-3-azabiciclo[3,1,0]-hexano, solvatos, hidratos y forma cristalina; composicion farmaceutica que comprende a dicho compuesto; | |
CR9432A (es) | Derivado de bencimidazol y uso como antagonista de angiotensina ii | |
NZ629636A (en) | Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions | |
WO2009062874A3 (en) | Benzimidazole derivatives and their use as fxr agonists | |
MX2009009344A (es) | Formas solidas de un inhibidor de cinasa raf. | |
UA102539C2 (ru) | Производные оксадиазола, активные в отношении сфингозин-1-фосфата (s1p) | |
ES2421587T3 (es) | Uso de derivados de pirimidilaminobenzamida para el tratamiento de mastocitosis sistémica | |
PE20080554A1 (es) | Formulacion acuosa del acido 4-[((4-carboxibutil)-{2-[(4-fenetilbencil)oxi]fenil}amino)metil]benzoico | |
NZ609964A (en) | Pharmaceutical compositions |